Close Menu

This article has been updated from a previous version to include comments made by Veracyte executives during the company's earnings call.

NEW YORK – Genomic testing firm Veracyte reported after the close of the market Tuesday that its third quarter 2019 revenues grew 32 percent year over year.

For the three months ended Sept. 30, the South San Francisco, California-based firm reported total revenues of $31.0 million, compared to $23.5 million in Q3 2018, beating analysts' average estimate of $30.1 million.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Jul
14

This webinar will describe a rapid metagenomics assay under development for human pathogens, including the SARS-CoV-2 coronavirus.

Jul
15
Sponsored by
LGC SeraCare Life Sciences

Cancer immunotherapy is an exciting new advance for the successful treatment of many forms of metastatic cancer.

Jul
23

This webinar will discuss a study that set to assess the efficacy and safety of osimertinib in EGFR T790M positive non-small cell lung cancer (NSCLC) patients identified by using plasma sample and cobas EGFR Mutation test v2. This is the first prospective study to use liquid biopsy upfront to evaluate osimertinib efficacy.